On February 23, Gilead Sciences, Inc. announced that it has entered into a definitive agreement to acquire Arcellx, Inc. Under the terms of the agreement, Arcellx shareholders will receive $115 per share in cash at closing plus one contingent value right of $5 per share, representing an implied equity value of $7.8 billion payable at […]
The post Gilead Inks $7.8 Billion Deal to Purchase Arcellx appeared first on LevinPro Healthcare M&A – The latest healthcare M&A news.
